Finanzen von Skye Bioscience Inc (SKYE)SKYESkye Bioscience Inc

Evaluating the bottom line, Skye Bioscience, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -233.87%, provide a clear picture of how effectively SKYE converts its operational activities into shareholder value.

In the context of the broader market, SKYE competes directly with industry leaders such as XBIO and MGRX. With a market capitalization of $4.40M, it holds a significant position in the sector. When comparing efficiency, SKYE's gross margin of N/A stands against XBIO's 100.00% and MGRX's -342.77%. Such benchmarking helps identify whether Skye Bioscience, Inc. is trading at a premium or discount relative to its financial performance.

Skye Bioscience has shown a troubling financial performance with consistent net losses, including -$12,509,361 in Q1 2026 and a gross profit of $0.00 in Q4 2025, indicating severe operational challenges.